Editorial Comment

Editorial Comment

1300 MORBIDITY FOLLOWING RADICAL CYSTECTOMY 4. Prasad SM, Ferreria M, Berry AM et al: Surgical Apgar outcome score: perioperative risk assessment fo...

84KB Sizes 2 Downloads 14 Views

1300

MORBIDITY FOLLOWING RADICAL CYSTECTOMY

4. Prasad SM, Ferreria M, Berry AM et al: Surgical Apgar outcome score: perioperative risk assessment for radical cystectomy. J Urol 2009; 181: 1046.

10. Quek ML, Stein JP, Daneshmand S et al: A critical analysis of perioperative mortality from radical cystectomy. J Urol 2006; 175: 886.

from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.

5. Shabsigh A, Korets R, Vora KC et al: Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009; 55: 164.

11. Stein JP, Lieskovsky G, Cote R et al: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666.

16. Chang SS, Cookson MS, Baumgartner RG et al: Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J Urol 2002; 167: 2012.

6. Donat SM, Shabsigh A, Savage C et al: Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol 2009; 55: 177.

12. Rosario DJ, Becker M and Anderson JB: The changing pattern of mortality and morbidity from radical cystectomy. BJU Int 2000; 85: 427.

7. Lowrance WT, Rumohr JA, Chang SS et al: Contemporary open radical cystectomy: analysis of perioperative outcomes. J Urol 2008; 179: 1313. 8. Novotny V, Hakenberg OW, Wiessner D et al: Perioperative complications of radical cystectomy in a contemporary series. Eur Urol 2007; 51: 397. 9. Hollenbeck BK, Miller DC, Taub DA et al: The effects of adjusting for case mix on mortality and length of stay following radical cystectomy. J Urol 2006; 176: 1363.

13. Fairey A, Chetner M, Metcalfe J et al: Associations among age, comorbidity and clinical outcomes after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy database. J Urol 2008; 180: 128. 14. Fairey AS, Jacobsen NE, Chetner MP et al: Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy database. J Urol 2009; 182: 85. 15. Levey AS, Bosch JP, Lewis JB et al: A more accurate method to estimate glomerular filtration rate

17. Goodney PP, Stukel TA, Lucas FL et al: Hospital volume, length of stay, and readmission rates in high-risk surgery. Ann Surg 2003; 238: 161. 18. Bostrom PJ, Kossi J, Laato M et al: Risk factors for mortality and morbidity related to radical cystectomy. BJU Int 2009; 103: 191. 19. Joos D, Chen Q, Jirjis J et al: An electronic medical record in primary care: impact on satisfaction, work efficiency and clinic processes. AMIA Annu Symp Proc 2006; 394. 20. Stimson CJ: Crossing the quality chasm: CMS and value based purchasing. In: Vanderbilt Health Law and Public Policy Forum, vol. 2, Winter 2009. Nashville: Vanderbilt University Law School 2009.

EDITORIAL COMMENT This is an impressive and important series from a high volume center dealing with early complications occurring within 30 days and late complications occurring within 90 days after radical cystectomy. These data are helpful for decision making, especially for patients for whom major surgery is critical or when, in anticipation of high postoperative morbidity leading to readmission, prophylactic treatment may be advisable. Radical cystectomy is still the best and preferred option for the treatment of locally advanced bladder cancer.1 However, this is only if patients survive and comorbidities of the treatment are acceptable. We have to consider that like in many other series some of those 6.9% of patients dying of the surgical intervention might have had favorable disease and would have survived by applying bladder conserving noninvasive or minimally invasive strategies. Of the comorbidities ileus is one of the most frequently noted reasons for early readmission to hospitals. It seems that laparoscopic or robotic assisted laparoscopic cystectomy reduces bowel related side effects due to a more delicate handling of gastrointestinal segments and, therefore, may be able to decrease bowel problems in the future.2

Pyelonephritis, urinary tract infection and fever account for 25% and 20% of early and late complications, respectively, leading to readmission in this series. The rate of pyelonephritis was more commonly seen in patients with orthotopic neobladder compared to ileal conduit. Therefore, we have to rethink the postoperative regimen with regard to type and length of postoperative antimicrobial and maybe antifungal treatment. The gender related difference in the readmission rate is surprising. It is difficult to find a clue for this significant difference. In a recent study a gender and race related difference was seen with regard to early tumor progression in favor of men but it is improbable that this in any way affected 90-day morbidity.3 Bowel related problems, pyelonephritis, and other inflammatory and infectious complications are important for the decision of whether to perform cystectomy and for the possible application of prophylactic treatment. However, patient gender alone should not be of any consequence with regard to the indication for cystectomy or the type of urinary diversion until we know the cause. Arnulf Stenzl Department of Urology Eberhard-Karls University Tübingen, Germany

REFERENCES 1. Stenzl A, Cowan NC, De Santis M et al: The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009; 55: 815.

2. Pruthi RS, Nielsen ME, Nix J et al: Robotic radical cystectomy for bladder cancer: surgical and pathological outcomes in 100 consecutive cases. J Urol 2010; 183: 510.

3. Scosyrev E, Noyes K, Feng C et al: Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 2009; 115: 68.